youtube_live
Utili Q3 2026 • pubblicata • Fatturato superato +11,84%
Esamina i risultatichevron_right
EVT:ETR
Evotec
3,15 €
arrow_upward
+1,88%(+0,058) 1G
6 nov, 16:45:35 GMT+1 · EUR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per EVT in corso…
Apertura
3,09 €
Massimo
3,19 €
Minimo
3,03 €
Cap. mercato
560,90 Mln
Vol. medio
1,20 Mln
Volume
822,55K
Max 52 sett.
6,73 €
Min 52 sett.
2,41 €
Utili per azione
-1,11 €
Azioni in circolazione
177,91 Mln
N. di dipendenti
4K
Apertura
3,09 €
Massimo
3,19 €
Minimo
3,03 €
Cap. mercato
560,90 Mln
Vol. medio
1,20 Mln
Volume
822,55K
Max 52 sett.
6,73 €
Min 52 sett.
2,41 €
Utili per azione
-1,11 €
Azioni in circolazione
177,91 Mln
N. di dipendenti
4K
Articoli giornalistici
Da fonti web e partner giornalistici
Yahoo Finance
·
14 ore fa
Evotec SE (EVOTF) (Q3 2026) Earnings Call Highlights: Near-Breakeven EBITDA, Horizon Savings ...
Yahoo Finance
·
19 ore fa
What Evotec (EVO) Said on Its Q3 Earnings Call
Investing.com UK
·
1 giorno fa
Evotec SE ADR earnings beat by $0.09, revenue topped estimates
www.marketscreener.com
·
1 giorno fa
Evotec Cuts 2030 Revenue Target, Restructuring Moves Forward
Profilo
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Informazioni su Evotec